Clinical associations and prognosis in Asian and European patients with symptom-controlled atrial fibrillation: Insights from two prospective registries in Europe and Asia.

IF 4.4 3区 医学 Q1 MEDICINE, GENERAL & INTERNAL
Wee Siong Teo, Manlin Zhao, Tommaso Bucci, Steven Ho Man Lam, Hongyu Liu, Yang Chen, Giuseppe Boriani, Hung-Fat Tse, Tze-Fan Chao, Gregory Y H Lip
{"title":"Clinical associations and prognosis in Asian and European patients with symptom-controlled atrial fibrillation: Insights from two prospective registries in Europe and Asia.","authors":"Wee Siong Teo, Manlin Zhao, Tommaso Bucci, Steven Ho Man Lam, Hongyu Liu, Yang Chen, Giuseppe Boriani, Hung-Fat Tse, Tze-Fan Chao, Gregory Y H Lip","doi":"10.1111/eci.70086","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Clinical associations and prognosis of patients with symptom-controlled AF (scAF) remain poorly understood.</p><p><strong>Methods: </strong>We analysed data from the Asian-Pacific Heart Rhythm Society and EURObservational Research Programme registries. Based on the European Heart Rhythm Association (EHRA) score, patients were classified as scAF (EHRA I or II) or symptomatic AF (EHRA III or IV). Clinical characteristics were examined by logistic regression, and prognosis was assessed by Cox models. The primary outcome was composed of all-cause death and major cardiovascular events. Interaction analyses were performed to investigate ethnic differences.</p><p><strong>Results: </strong>Among 13,577 AF patients (mean age 69.0 ± 11.6 years; 38.7% female), 11,470 (84.5%) had scAF. Asians were more likely to be scAF, characterised by younger age and lower cardiovascular burden compared to Europeans. Diabetes mellitus was significantly associated with scAF only in Asians (adjusted odd ratio [aOR] 1.43, 95% confidence interval [CI] 1.03-2.04, p<sub>interaction</sub> = 0.021). The associations with hypertension (aOR 1.29, 95% CI 0.98-1.70, p<sub>interaction</sub> = 0.004) and prior ischemic stroke (aOR 1.75, 95% CI 0.96-3.58, p<sub>interaction</sub> = 0.045) were more evident in Asians. Patients with scAF showed a notable association with increased likelihood of using vitamin K antagonists (aOR 1.19, 95% CI 1.07-1.33), which was more prominent in Asians. In both Asians and Europeans, scAF was associated with reduced rhythm control management. Compared to non-scAF, European patients with scAF had a reduced risk of the composite outcome, but the association was non-significant in Asians (p<sub>interaction</sub> = 0.594).</p><p><strong>Conclusion: </strong>Asians and Europeans with scAF demonstrate clinically relevant differences in terms of overall prevalence, related risk factors, and clinical management.</p>","PeriodicalId":12013,"journal":{"name":"European Journal of Clinical Investigation","volume":" ","pages":"e70086"},"PeriodicalIF":4.4000,"publicationDate":"2025-06-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Clinical Investigation","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/eci.70086","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Clinical associations and prognosis of patients with symptom-controlled AF (scAF) remain poorly understood.

Methods: We analysed data from the Asian-Pacific Heart Rhythm Society and EURObservational Research Programme registries. Based on the European Heart Rhythm Association (EHRA) score, patients were classified as scAF (EHRA I or II) or symptomatic AF (EHRA III or IV). Clinical characteristics were examined by logistic regression, and prognosis was assessed by Cox models. The primary outcome was composed of all-cause death and major cardiovascular events. Interaction analyses were performed to investigate ethnic differences.

Results: Among 13,577 AF patients (mean age 69.0 ± 11.6 years; 38.7% female), 11,470 (84.5%) had scAF. Asians were more likely to be scAF, characterised by younger age and lower cardiovascular burden compared to Europeans. Diabetes mellitus was significantly associated with scAF only in Asians (adjusted odd ratio [aOR] 1.43, 95% confidence interval [CI] 1.03-2.04, pinteraction = 0.021). The associations with hypertension (aOR 1.29, 95% CI 0.98-1.70, pinteraction = 0.004) and prior ischemic stroke (aOR 1.75, 95% CI 0.96-3.58, pinteraction = 0.045) were more evident in Asians. Patients with scAF showed a notable association with increased likelihood of using vitamin K antagonists (aOR 1.19, 95% CI 1.07-1.33), which was more prominent in Asians. In both Asians and Europeans, scAF was associated with reduced rhythm control management. Compared to non-scAF, European patients with scAF had a reduced risk of the composite outcome, but the association was non-significant in Asians (pinteraction = 0.594).

Conclusion: Asians and Europeans with scAF demonstrate clinically relevant differences in terms of overall prevalence, related risk factors, and clinical management.

亚洲和欧洲症状控制性心房颤动患者的临床关联和预后:来自欧洲和亚洲两个前瞻性登记的见解
背景:症状控制性房颤(scAF)患者的临床关联和预后尚不清楚。方法:我们分析了来自亚太心律学会和欧洲观察研究计划登记处的数据。根据欧洲心律协会(EHRA)评分,将患者分为scAF (EHRA I或II)或症状性AF (EHRA III或IV)。采用logistic回归分析临床特征,采用Cox模型评价预后。主要结局包括全因死亡和主要心血管事件。相互作用分析用于调查种族差异。结果:13577例房颤患者(平均年龄69.0±11.6岁;38.7%女性),11470例(84.5%)有scAF。与欧洲人相比,亚洲人患scAF的可能性更大,其特点是年龄更年轻,心血管负担更低。糖尿病仅在亚洲人中与scAF显著相关(调整奇数比[aOR] 1.43, 95%可信区间[CI] 1.03-2.04,相互作用= 0.021)。与高血压(aOR 1.29, 95% CI 0.98-1.70, p相互作用= 0.004)和既往缺血性卒中(aOR 1.75, 95% CI 0.96-3.58, p相互作用= 0.045)的相关性在亚洲人中更为明显。scAF患者与使用维生素K拮抗剂的可能性增加显著相关(aOR 1.19, 95% CI 1.07-1.33),这在亚洲人中更为突出。在亚洲人和欧洲人中,scAF与心律控制管理降低有关。与非scAF相比,欧洲scAF患者的综合结局风险降低,但亚洲患者的相关性不显著(p - interaction = 0.594)。结论:亚洲人和欧洲人scAF患者在总体患病率、相关危险因素和临床管理方面存在临床相关差异。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
9.50
自引率
3.60%
发文量
192
审稿时长
1 months
期刊介绍: EJCI considers any original contribution from the most sophisticated basic molecular sciences to applied clinical and translational research and evidence-based medicine across a broad range of subspecialties. The EJCI publishes reports of high-quality research that pertain to the genetic, molecular, cellular, or physiological basis of human biology and disease, as well as research that addresses prevalence, diagnosis, course, treatment, and prevention of disease. We are primarily interested in studies directly pertinent to humans, but submission of robust in vitro and animal work is also encouraged. Interdisciplinary work and research using innovative methods and combinations of laboratory, clinical, and epidemiological methodologies and techniques is of great interest to the journal. Several categories of manuscripts (for detailed description see below) are considered: editorials, original articles (also including randomized clinical trials, systematic reviews and meta-analyses), reviews (narrative reviews), opinion articles (including debates, perspectives and commentaries); and letters to the Editor.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信